Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALE.P02 alone or with pembrolizumab in CLDN1-positive advanced squamous solid tumors
2024-515459-39-00Phase 2Authorised
- Sponsor
- Alentis Therapeutics
- Start
- May 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, open-label trial of ALE.P02 and pembrolizumab in Pulmonary squamous cell carcinoma, head and neck squamous cell carcinoma (HNSCC), nasopharyngeal carcinoma (NPC) and 2 more (2 arms), sponsored by Alentis Therapeutics. Primary endpoints: Dose-limiting toxicities, Adverse events and serious adverse events and 4 more. Planned start May 2025; status: authorised.
02
Drugs
ALE.P02pembrolizumab
03
Conditions
Pulmonary squamous cell carcinomahead and neck squamous cell carcinoma (HNSCC)nasopharyngeal carcinoma (NPC)Esophageal Squamous Cell Carcinoma (ESCC)cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on 2024-515459-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515459-39-00.